Table 3

Coefficients of the brain, liver, spleen, heart and kidney
Groups Body weight (g) Brain (mg/g) Liver (mg/g) Heart (mg/g) Spleen (mg/g) Kidney (mg/g)
ZALH (n = 8) 300 ± 25 5.61 ± 0.93 35.67 ± 1.53 4.00 ± 0.53 1.99 ± 0.37 4.19 ± 0.20
ZALL (n = 8) 342 ± 30 5.76 ± 0.55 36.27 ± 3.35 3.90 ± 0.53 2.08 ± 0.20 4.16 ± 0.22
ZAH (n = 8) 337 ± 25 5.62 ± 0.31 30.14 ± 3.54 3.91 ± 0 .43 2.32 ± 0.26 3.98 ± 0. 23
ZAL (n = 8) 335 ± 47 5.22 ± 0.68 31.83 ± 4.12 4.50 ± 0.44 2.29 ± 0.19 3.93 ± 0.45
VC (n = 8) 332 ± 14 5.31 ± 0.70 28.25 ± 2.71 3.86 ± 0 .35 1.88 ± 0.19 3.59 ± 0.39

Mean coefficient of brain, liver, spleen, heart and kidney of all the groups. The coefficients of organs from the four treated groups were almost similar to those of the control. Statistical test used to compare the means of each group against the control group was done using one-way ANOVA; it shows no significant difference with p > 0.05. Zinc-aluminium levodopa nanocomposite high dose (ZALH 500 mg/kg), zinc-aluminium levodopa nanocomposite low dose (ZALL 5 mg/kg), zinc-aluminium nanocomposite high dose (ZAH 500 mg/kg), zinc-aluminium nanocomposite low dose (ZAL 5 mg/kg), vehicle control (VC normal saline 100 ml/kg body weight).

Kura et al.

Kura et al. Nanoscale Research Letters 2014 9:261   doi:10.1186/1556-276X-9-261

Open Data